Comparing inhaled and intravenous milrinone for severe pulmonary hypertension during heart surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of inhaled versus intravenous milrinone in patients with severe pulmonary hypertension who are scheduled for cardiac surgery. Milrinone is commonly used as an inotropic agent and pulmonary vasodilator, but intravenous administration can lead to systemic hypotension and increased need for other vasoactive medications. By comparing these two methods of administration, the study aims to determine which approach is more effective and safer for patients undergoing mitral valve surgery. The study will involve patients with a specific mean pulmonary artery pressure as assessed by preoperative echocardiography.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients scheduled to undergo mitral valve surgery by cardiopulmonary bypass with estimated mean pulmonary artery pressure =\>55 estimated by using preoperative Doppler echocardiography

Exclusion Criteria:

Patients were excluded if they had surgery without CPB, preoperative hemodynamic instability (defined as acute requirement for vasoactive support or mechanical device),Patients with severe LV dysfunction (LV ejection fraction of less than 30% congenital heart disease, a contraindication to transesophageal echocardiography (TEE), emergency surgery or re-do surgeries severe renal or hepatic disease

, coagulopathy, and thromboembolic disease treated with anticoagulants

Where it's running

• Zagazig University
  Zagazig, Sharqia Province, Egypt Recruiting

Study contacts

• Principal investigator: Heba M EL-Asser, MD — Zagazig University
• Study coordinator: Heba M EL-Asser, MD
• Email: aseelaswad1@yahoo.com
• Phone: 01062393152

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BMPR2-Activin signaling in pulmonary hypertension from left heart disease

  This project will test whether changes in the BMPR2-activin pathway drive lung vessel disease in people with heart failure and pulmonary hypertension by following 150 patients for one year.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid, Madrid · NCT07537517

• Registry and biorepository for pulmonary hypertension patients

  This study is setting up a collection of health information and blood samples from people with pulmonary hypertension to help researchers learn more about the disease and improve treatments.

  Recruiting University of Kansas Medical Center · Kansas City, Kansas · NCT04808596

• Adding sotatercept to usual therapy for adults with Eisenmenger syndrome or unrepaired shunt-related pulmonary arterial hypertension

  This study will test whether giving sotatercept in addition to standard PAH medicines helps adults with Eisenmenger syndrome or unrepaired shunt-associated pulmonary arterial hypertension that has not improved enough on vasodilators.

  Recruiting at 10 sites Phase 4 Kyushu University · Fukuoka, Not Required For This Country and 9 other locations · NCT07356778

• Rutgers Genetics of Pulmonary Hypertension

  This online project will try to see if genetic differences affect the risk of pulmonary hypertension in U.S. adults, and anyone 18 or older can join whether or not they have PH.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07217522

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.